Retatrutide
GIP/GLP-1/Glucagon Triple Agonist (Investigational)
Phase-2 randomized trials show large weight and glycemic effects, but retatrutide is investigational — efficacy and safety are not yet established by phase-3 or long-term data.
How confident is BioSignal?
Our overall position, and how sure we are of it across each dimension — including where we are not sure at all.
Moderate confidence
Phase-2 randomized trials show large weight and glycemic effects, but retatrutide is investigational — efficacy and safety are not yet established by phase-3 or long-term data.
Promising evidence that is still developing or context-dependent.
Human Evidence
Real randomized phase-2 trials (obesity, type 2 diabetes); no phase-3 or outcome data yet.
Mechanistic Plausibility
Triple GIP/GLP-1/glucagon agonism; glucagon adds energy expenditure and hepatic effects.
Research Activity
Phase-3 program ongoing; high interest.
Safety Profile
Class GI effects; glucagon component raises heart rate and can raise glucose at high doses; short follow-up.
Consistency
Consistent across the two phase-2 trials, but a small evidence base.
Consensus
No guideline status; investigational.
Where the evidence stands today
How mature the science is, what kinds of evidence exist, and — the part nobody else prints — what is still missing.
5/9
steps proven in humans
Partly established
3 steps not demonstrated: Large human RCTs · Clinical outcomes · Guideline / regulatory support
Guideline / regulatory support
Not shownNot approved.
Clinical outcomes
Not shownNo hard-outcome data.
Large human RCTs
Not shownPhase-3 ongoing; none reported.
Small human outcome trials
ProvenPhase-2 obesity and diabetes RCTs.
Human safety data
LimitedPhase-2 only; short follow-up.
Human biomarker / pharmacology
ProvenWeight and glycemic effects in trials.
Animal
ProvenPreclinical program.
Cell / in vitro
ProvenReceptor pharmacology.
Mechanistic plausibility
ProvenTriple GIP/GLP-1/glucagon agonism.
The bottom line
What we know, what we think, what we don't know — and what would change our mind.
Large phase-2 effects
In a phase-2 obesity trial, retatrutide produced ~24% mean weight loss at 48 weeks, and improved glycemia and weight in a phase-2 type-2-diabetes trial.
Promising, if confirmed
The triple-agonist mechanism may push weight loss beyond current dual/mono agonists — if phase 3 confirms efficacy and safety.
Everything phase 3 exists to answer
Durable efficacy, cardiovascular and other hard outcomes, long-term safety, and the significance of glucagon-related effects.
Phase-3 ongoing
Phase-3 obesity, diabetes, and related trials are underway.
What would change the picture
Positive phase-3 data and approval would move maturity to Established; a safety signal or failed phase 3 would downgrade the outlook.
The biggest myth
“Retatrutide is available or approved.”
It is investigational; not FDA-approved; obtaining it outside a trial means an unapproved product of unknown quality.
Ask BioSignal
Still have a question about retatrutide?
Answers are retrieved from this record and the rest of the knowledge graph — never generated.
Why people take retatrutide
Popularity is not evidence — but it is not stupid either. This explains the interest on its own terms.
People search retatrutide as the "next-generation weight-loss peptide" with the largest reported effects. Interest far outruns availability and proof: it is investigational, phase-2, and not an approved or evaluated therapy — the excitement is anticipatory, not established.
If you're here because…
Jump straight to the part of the evidence that answers your question.
Approval, safety and regulatory
What it is approved for, who should be careful, what remains unknown — and the limits of what this evidence can tell you.
Regulatory status
Investigational (not approved)
Availability
Investigational — clinical trials only
Sport (WADA)
Not a listed class; investigational (confirm at publication)
Known safety profile
From phase 2: class-typical gastrointestinal effects; increased heart rate and, at higher doses, transient glucose increases attributable to the glucagon component.
Common issues
- Nausea and other GI effects
- Increased heart rate
- Transient glucose rise at higher doses
Use caution if
- Everyone — investigational, safety not established
- Anyone sourcing unapproved product of unknown identity/purity
Long-term unknowns
Essentially all long-term safety and outcome data.
Limits of this evidence
Small, short, industry-sponsored phase-2 base; no phase-3 or outcome data.
Full regulatory and sport detail
- Regulatory approval
- None — investigational.
- Approved indication
- None.
- Investigational
- Phase-3 obesity/diabetes program ongoing.
- Research chemical
- Obtaining it outside a trial means an unapproved product of unknown quality.
- Sport (WADA)
- As an unapproved/investigational agent, athletes should not assume it is permitted — requires confirmation.
- Publication note
- Re-confirm regulatory and anti-doping status against primary sources at publication.
Demand, separated from evidence
Every claim people make about this, counted against what the evidence actually showed.
BioSignal evaluated 4 popular claims about retatrutide.
Here is where each one landed — including the claims of harm, where “not established” is reassuring rather than damning.
- Mixed evidence
- 1
- Not established
- 3
Popularity is not evidence. This is simply a count of every claim BioSignal evaluated on this page, sorted by what the evidence actually showed — the full reasoning behind each verdict is in the Evidence Review below.
Mixed evidence
- Retatrutide causes the largest weight loss of any incretin.
Not established
- Retatrutide is available or approved.
- Retatrutide is proven safe and effective.
- The triple mechanism is better.
The evidence review
Every claim with the reasoning behind its verdict, the doses actually studied, where scientists agree and disagree, and the questions still open.
What people claim
Every popular claim, with BioSignal’s verdict and how confident we are in it. The verdicts are always visible; open any claim to read the evidence behind it.
Retatrutide causes the largest weight loss of any incretin.MixedModerate confidence
Phase-2 results are the largest reported, but this is phase-2, short-term data — not head-to-head phase-3 proof.
Retatrutide is proven safe and effective.Not establishedHigh confidence
Efficacy and safety are not yet established; phase-3 and long-term data are pending.
The triple mechanism is better.Not establishedModerate confidence
Biologically plausible and phase-2-encouraging, but superiority to approved agents is not demonstrated in phase 3.
Doses used in human studies
What was actually given to participants in the research. These are descriptions of studies, not recommendations.
Adults with obesity
- Intervention
- Retatrutide SC weekly
- Dose
- investigational, titrated (up to 12 mg)
- Duration
- 48 weeks
- Outcome
- ~24% weight loss (phase 2)
- Notes
- Investigational; not an available therapy.
Type 2 diabetes
- Intervention
- Retatrutide SC weekly
- Dose
- investigational, titrated
- Duration
- 36 weeks
- Outcome
- HbA1c / weight (phase 2)
- Notes
- Not a recommendation.
Where scientists agree — and don’t
Agreed
- Phase-2 weight and glycemic effects are large and biologically plausible
Debated
- Whether added glucagon agonism yields net benefit or new risks
- Whether phase-2 magnitude will hold in phase 3
Unknown
- All hard outcomes, long-term safety, and real-world efficacy — pending phase 3
What remains unknown
- What are the phase-3 efficacy and safety results?
- What are the long-term consequences of glucagon-receptor agonism (heart rate, glucose, hepatic effects)?
- How durable is the effect, and how does it compare with approved incretins?
Questions people actually ask
Can I get retatrutide?
Not as an approved therapy — it is investigational and available only through clinical trials. Products sold outside trials are unapproved and of unknown quality and safety.
Is retatrutide better than semaglutide or tirzepatide?
Its phase-2 weight-loss numbers are the largest reported, but there are no phase-3 or head-to-head outcome data, so superiority is not established.
Practical takeaways
- Retatrutide is investigational — not approved and not an evaluated, available therapy.
- Phase-2 results are striking (~24% weight loss) but preliminary and short-term.
- The glucagon component raises specific questions (heart rate, glucose) that phase 3 must resolve.
- Sourcing it outside a trial means an unapproved product of unknown quality and safety.
- BioSignal will upgrade this record only if phase-3 evidence establishes efficacy and safety.
How it works
The mechanism comes last on purpose. A compelling explanation of how something might work is the easiest part of the story to tell, and the part most likely to outlive the evidence for it.
How we found out
2023 — Phase-2 obesity trial
~24% weight loss at 48 weeks.
2023 — Phase-2 type-2-diabetes trial
Improved HbA1c and weight.
Ongoing
Phase-3 program (efficacy, safety, outcomes).
References
Verified sources. BioSignal does not print a citation it has not checked.
- 01
Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial
N Engl J Med 389(6):514-526 · 2023
- 02
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
Lancet 402(10401):529-544 · 2023
Version history
1.0
Initial review-hardened record (Emerging; moderate confidence; investigational). Review cadence: Quarterly → Continuous Monitoring.
Continue exploring
Three places this record leads next.